Novavax (NASDAQ:NVAX) is a biotechnology firm focused on the development and commercialization of innovative vaccines to address serious infectious diseases. The company is particularly known for its work on vaccines for respiratory syncytial virus (RSV) and the coronavirus, with its NVX-CoV2373 vaccine candidate generating significant attention during the COVID-19 pandemic. Novavax aims to leverage its proprietary recombinant nanoparticle vaccine technology to create vaccine options that can improve global health outcomes. Its objectives include achieving regulatory approval for its vaccine candidates, increasing manufacturing capabilities, and forming strategic partnerships to ensure global distribution. By focusing on these goals, Novavax strives to meet the urgent need for effective vaccines, particularly in underserved populations around the world.